Pub Date : 2006-08-01DOI: 10.1111/j.1600-0781.2006.00243.x
T. Ruenger
{"title":"Photodermatology, edited by James Ferguson and Jeffrey S. Dover","authors":"T. Ruenger","doi":"10.1111/j.1600-0781.2006.00243.x","DOIUrl":"https://doi.org/10.1111/j.1600-0781.2006.00243.x","url":null,"abstract":"","PeriodicalId":20104,"journal":{"name":"Photodermatology, Photoimmunology and Photomedicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2006-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88436961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-08-01DOI: 10.1034/J.1600-0781.2002.00777.X
M. Zanolli
{"title":"Photobiology for the 21st Century.Thomas Coohill and Dennis Valenzeno (eds)","authors":"M. Zanolli","doi":"10.1034/J.1600-0781.2002.00777.X","DOIUrl":"https://doi.org/10.1034/J.1600-0781.2002.00777.X","url":null,"abstract":"","PeriodicalId":20104,"journal":{"name":"Photodermatology, Photoimmunology and Photomedicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80043171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-04-01DOI: 10.1034/J.1600-0781.2002.180208_10.X
A. Kontos, D. Ozog, H. Lim
Congenital erythropoietic porphyria is a rare autosomal recessive disease due to the deficient activity of uroporphyrinogen III synthase, the fourth enzyme in the porphyrin-heme synthetic pathway. Of the porphyrias, it is the most mutilating type, usually presenting early in life. We present a patient who developed skin fragility of sun-exposed skin and red urine at the age of 72 years. Porphyrin profile showed plasma maximum fluorescence at neutral pH of 617 nm. In plasma, urine and erythrocytes, the predominant porphyrins were uroporphyrin and coproporphyrin. In all specimens, isomer I predominated. Urine δ-aminolevulinic acid and porphobilinogen, and erythrocyte uroporphyrinogen decarboxylase levels were within nomal limits. These finding were consistent with congenital erythropoietic porphyria. Thrombocytopenia and myelodysplasia with bone-marrow sideroblasts were also incidentally discovered. Including our patient, only 12 cases of late onset congenital erythropoietic porphyria have been reported worldwide, with our patient being the oldest. Patients who develop late onset congenital erythropoietic porphyria develop less severe manifestations, possibly due to heterogeneous mutations in the defective enzyme. Of the 12 reported cases, seven had thrombocytopenia, six of which also had myelodysplasia.
{"title":"010 Late onset congenital erythropoietic porphyria (Günther's disease)","authors":"A. Kontos, D. Ozog, H. Lim","doi":"10.1034/J.1600-0781.2002.180208_10.X","DOIUrl":"https://doi.org/10.1034/J.1600-0781.2002.180208_10.X","url":null,"abstract":"Congenital erythropoietic porphyria is a rare autosomal recessive disease due to the deficient activity of uroporphyrinogen III synthase, the fourth enzyme in the porphyrin-heme synthetic pathway. Of the porphyrias, it is the most mutilating type, usually presenting early in life. We present a patient who developed skin fragility of sun-exposed skin and red urine at the age of 72 years. Porphyrin profile showed plasma maximum fluorescence at neutral pH of 617 nm. In plasma, urine and erythrocytes, the predominant porphyrins were uroporphyrin and coproporphyrin. In all specimens, isomer I predominated. Urine δ-aminolevulinic acid and porphobilinogen, and erythrocyte uroporphyrinogen decarboxylase levels were within nomal limits. These finding were consistent with congenital erythropoietic porphyria. Thrombocytopenia and myelodysplasia with bone-marrow sideroblasts were also incidentally discovered. Including our patient, only 12 cases of late onset congenital erythropoietic porphyria have been reported worldwide, with our patient being the oldest. Patients who develop late onset congenital erythropoietic porphyria develop less severe manifestations, possibly due to heterogeneous mutations in the defective enzyme. Of the 12 reported cases, seven had thrombocytopenia, six of which also had myelodysplasia.","PeriodicalId":20104,"journal":{"name":"Photodermatology, Photoimmunology and Photomedicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76550090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-04-01DOI: 10.1034/J.1600-0781.2002.180208_9.X
N. Kolias, G. Stamatas
Fluoresence excitation spectroscopy of skin is a noninvasive method for objective evaluations of skin aging and photoaging. Fluoresence bands in the UV have been assigned to tryptophan moieties, pepsin digestible collagen cross-links (PDCCL), collagenase digestible collagen cross-links (CDCCL) and elastin cross-links. We have studied the dependence of these bands to aging and photoaging in the hairless mouse model and in humans. In the mouse, gluorescence of the tryptophan moieties decreases linearly with age, while the fluorescence band due to PDCCL increases linearly with age. In contrast, chronically UVB exposed mice showed an increase in the tryptophan band and a dramatic reduction of the PDCCL band compared to age-matched controls. The same phenomena were observed on mouse skin immediately after UVA exposure. The dependence of fluorescence of human facial skin with aging was studied in a large population sample (> 500 people in total) ages 15–70 at five geographic locations. Similar to the mouse model we observed a decrease in the tryptophan fluorescence signal, which is probably related to the reduction of the cell turnover rate with aging. Furthermore, observed increases in the fluorescence signals corresponding to collagen and elastin cross-links with aging may be attributed to chronic accumulation of cross-links in these long-lived molecules. The fluorescence ratio of the elastin cross-links signal to that of tryptophan moieties correlates strongly with age and is independent of geographical region and seasonal effects. The same fluorescence ratio has been used to monitor the antiaging effects of retinol treatment.
{"title":"009 Skin aging and photoaging effects can be quantified in vivo by fluoresence excitation spectroscopy","authors":"N. Kolias, G. Stamatas","doi":"10.1034/J.1600-0781.2002.180208_9.X","DOIUrl":"https://doi.org/10.1034/J.1600-0781.2002.180208_9.X","url":null,"abstract":"Fluoresence excitation spectroscopy of skin is a noninvasive method for objective evaluations of skin aging and photoaging. Fluoresence bands in the UV have been assigned to tryptophan moieties, pepsin digestible collagen cross-links (PDCCL), collagenase digestible collagen cross-links (CDCCL) and elastin cross-links. We have studied the dependence of these bands to aging and photoaging in the hairless mouse model and in humans. In the mouse, gluorescence of the tryptophan moieties decreases linearly with age, while the fluorescence band due to PDCCL increases linearly with age. In contrast, chronically UVB exposed mice showed an increase in the tryptophan band and a dramatic reduction of the PDCCL band compared to age-matched controls. The same phenomena were observed on mouse skin immediately after UVA exposure. The dependence of fluorescence of human facial skin with aging was studied in a large population sample (> 500 people in total) ages 15–70 at five geographic locations. Similar to the mouse model we observed a decrease in the tryptophan fluorescence signal, which is probably related to the reduction of the cell turnover rate with aging. Furthermore, observed increases in the fluorescence signals corresponding to collagen and elastin cross-links with aging may be attributed to chronic accumulation of cross-links in these long-lived molecules. The fluorescence ratio of the elastin cross-links signal to that of tryptophan moieties correlates strongly with age and is independent of geographical region and seasonal effects. The same fluorescence ratio has been used to monitor the antiaging effects of retinol treatment.","PeriodicalId":20104,"journal":{"name":"Photodermatology, Photoimmunology and Photomedicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77734874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-04-01DOI: 10.1034/J.1600-0781.2002.180208_11.X
A. Kontos, C. Cusack, H. Lim
Polymorphous light eruption (PMLE) is the most common chronic idiopathic photodermatosis with a prevalence estimated at 10-20% and a genetic predisposition from 5-45%. It tends to occur in the spring with gradual resolution as summer progresses. Papular eruptions are most commonly seen, however, several morphological variants exist among affected individuals, including vesicular, eczematous and papulovesicular lesions. Lesions are usually monomorphic in a given patient. We present nine African-American female patients in whom PMLE manifests as a pinpoint papular variant, which has not been commonly described previously. Of the four patients who were phototested, one had an abnormal UVA MED result of 12 J/cm2. Histopathologic findings revealed perivascular and focal lichenoid lymphohistiocytic infiltrate with papillary dermal hemorrhage in all biopsy specimens.
{"title":"011 Polymorphous light eruption (PMLE) in African‐Americans presenting as pinpoint papules","authors":"A. Kontos, C. Cusack, H. Lim","doi":"10.1034/J.1600-0781.2002.180208_11.X","DOIUrl":"https://doi.org/10.1034/J.1600-0781.2002.180208_11.X","url":null,"abstract":"Polymorphous light eruption (PMLE) is the most common chronic idiopathic photodermatosis with a prevalence estimated at 10-20% and a genetic predisposition from 5-45%. It tends to occur in the spring with gradual resolution as summer progresses. Papular eruptions are most commonly seen, however, several morphological variants exist among affected individuals, including vesicular, eczematous and papulovesicular lesions. Lesions are usually monomorphic in a given patient. We present nine African-American female patients in whom PMLE manifests as a pinpoint papular variant, which has not been commonly described previously. Of the four patients who were phototested, one had an abnormal UVA MED result of 12 J/cm2. Histopathologic findings revealed perivascular and focal lichenoid lymphohistiocytic infiltrate with papillary dermal hemorrhage in all biopsy specimens.","PeriodicalId":20104,"journal":{"name":"Photodermatology, Photoimmunology and Photomedicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83436357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-04-01DOI: 10.1034/J.1600-0781.2002.180208_12.X
H. Lui, L. Hobbs, W. Tope, C. Elmets, N. Provost, Peter K. Lee, K. Herne, D. McLean, I. Hamzavi, Hem Jain, R. Bissonnette
Introduction and objectives: Photodynamic therapy (PDT) with verteporfin may be particularly well suited for patients with multiple low risk non-melanoma skin cancers (NMSC) while providing good cosmetic outcomes as compared to standard treatments. The objectives of this study were to prospectively assess the tumor responses and cosmetic outcomes of verteporfin-treated NMSC. Patients and methods: This was a phase 11, open-label, light-dose ranging, multicenter study of 54 patients with multiple NMSC. A total of 421 biopsy-proven tumors that were either basal cell carcinomas or in situ squamous cell carcinomas underwent PDT with intravenous verteporfin 14 mg/m2 followed by exposure to red light from LED diode arrays (658-718 nm FWHM) at fluences of 60, 120, or 180 J/cm2. Each patient was randomly assigned to receive one of the three light doses to all their tumors. Treated tumors underwent follow up biopsies at 6 months after the initial PDT session to determine the pathologic complete response rate. In addition, the treated tumors were assessed clinically for up to 24 months. The cosmetic outcome of each treated tumor site was assessed by the investigators based on color, profile, and surface texture. Results: The pathologic complete response rates at 6 months were 69, 79, and 93% for the 60, 120 and 180 J/cm2 light fluences, respectively. The clinical complete response rates by tumor at 6 months were 78, 89 and 98% at 60, 120 and 180 J/cm2, respectively, while at 24 months, the corresponding rates were 51, 79, and 95%. The cosmetic outcome by tumor at 24 months judged by the investigator to have achieved at least a satisfactory or higher outcome was 92, 76, and 86% at 60, 120 and 180 J/cm2, respectively. Conclusions: PDT of NMSC with verteporfin provides effective tumor clearing that is dose-dependent with satisfactory to excellent outcomes in the majority of patients.
{"title":"012 Photodynamic therapy of non‐melanoma skin cancers with verteporfin and red light – tumor response and cosmetic outcome","authors":"H. Lui, L. Hobbs, W. Tope, C. Elmets, N. Provost, Peter K. Lee, K. Herne, D. McLean, I. Hamzavi, Hem Jain, R. Bissonnette","doi":"10.1034/J.1600-0781.2002.180208_12.X","DOIUrl":"https://doi.org/10.1034/J.1600-0781.2002.180208_12.X","url":null,"abstract":"Introduction and objectives: Photodynamic therapy (PDT) with verteporfin may be particularly well suited for patients with multiple low risk non-melanoma skin cancers (NMSC) while providing good cosmetic outcomes as compared to standard treatments. The objectives of this study were to prospectively assess the tumor responses and cosmetic outcomes of verteporfin-treated NMSC. \u0000 \u0000 \u0000 \u0000Patients and methods: This was a phase 11, open-label, light-dose ranging, multicenter study of 54 patients with multiple NMSC. A total of 421 biopsy-proven tumors that were either basal cell carcinomas or in situ squamous cell carcinomas underwent PDT with intravenous verteporfin 14 mg/m2 followed by exposure to red light from LED diode arrays (658-718 nm FWHM) at fluences of 60, 120, or 180 J/cm2. Each patient was randomly assigned to receive one of the three light doses to all their tumors. Treated tumors underwent follow up biopsies at 6 months after the initial PDT session to determine the pathologic complete response rate. In addition, the treated tumors were assessed clinically for up to 24 months. The cosmetic outcome of each treated tumor site was assessed by the investigators based on color, profile, and surface texture. \u0000 \u0000 \u0000 \u0000Results: The pathologic complete response rates at 6 months were 69, 79, and 93% for the 60, 120 and 180 J/cm2 light fluences, respectively. The clinical complete response rates by tumor at 6 months were 78, 89 and 98% at 60, 120 and 180 J/cm2, respectively, while at 24 months, the corresponding rates were 51, 79, and 95%. The cosmetic outcome by tumor at 24 months judged by the investigator to have achieved at least a satisfactory or higher outcome was 92, 76, and 86% at 60, 120 and 180 J/cm2, respectively. \u0000 \u0000 \u0000 \u0000Conclusions: PDT of NMSC with verteporfin provides effective tumor clearing that is dose-dependent with satisfactory to excellent outcomes in the majority of patients.","PeriodicalId":20104,"journal":{"name":"Photodermatology, Photoimmunology and Photomedicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78724577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-04-01DOI: 10.1034/J.1600-0781.2002.180208_21.X
A. Taneja, M. Trehan, S. Gupta, A. Racette, S. Regan, Zafirios Gourgouliatos, C. R. Taylor
This work-in-progress evaluates the efficacy of a unique UVB fiber optic comb device for treating scalp psoriasis. Informed consent was obtained on 11 enrolled patients. One scalp psoriasis plaque was left as a control, while another was selected for treatment. An MED was performed on the lower back or gluteal skin to determine the subject's baseline sensitivity to the comb device. On the selected sit, mineral oil was first applied with a soaked gauze to enhance UV delivery and the first treatment was at 1 MED. Subsequent treatments were thrice weekly at 72 h intervals with maximum increments of 20% per treatment. Treatments ended after 12 weeks or when clearing occurred, whichever came first. Clinical evaluation and standardized photographs were taken at baseline and every 2 weeks thereafter. Results On average, patients have received 24 treatments (range: 2–36). At baseline, PASI scores for the treated and control sides did not differ significantly (mean difference: 0.4, P= 0.1106). Improvement scores, calculated by subtracting the most recent PASI score from the baseline value, were higher for the treated sides (3.9 vs. 0.3, P = 0.0002). Three patients showed worsening in the control area. Ten of the 11 patients showed improvement in the treated area; none experienced worsening of symptoms. Conclusions The fiber optic brush offers an exciting potential for treating scalp psoriasis.
{"title":"021 UVB emitting fiber optic hair brush for the treatment of scalp psoriasis","authors":"A. Taneja, M. Trehan, S. Gupta, A. Racette, S. Regan, Zafirios Gourgouliatos, C. R. Taylor","doi":"10.1034/J.1600-0781.2002.180208_21.X","DOIUrl":"https://doi.org/10.1034/J.1600-0781.2002.180208_21.X","url":null,"abstract":"This work-in-progress evaluates the efficacy of a unique UVB fiber optic comb device for treating scalp psoriasis. Informed consent was obtained on 11 enrolled patients. One scalp psoriasis plaque was left as a control, while another was selected for treatment. An MED was performed on the lower back or gluteal skin to determine the subject's baseline sensitivity to the comb device. On the selected sit, mineral oil was first applied with a soaked gauze to enhance UV delivery and the first treatment was at 1 MED. Subsequent treatments were thrice weekly at 72 h intervals with maximum increments of 20% per treatment. Treatments ended after 12 weeks or when clearing occurred, whichever came first. Clinical evaluation and standardized photographs were taken at baseline and every 2 weeks thereafter. \u0000 \u0000 \u0000 \u0000Results On average, patients have received 24 treatments (range: 2–36). At baseline, PASI scores for the treated and control sides did not differ significantly (mean difference: 0.4, P= 0.1106). Improvement scores, calculated by subtracting the most recent PASI score from the baseline value, were higher for the treated sides (3.9 vs. 0.3, P = 0.0002). \u0000 \u0000 \u0000 \u0000Three patients showed worsening in the control area. Ten of the 11 patients showed improvement in the treated area; none experienced worsening of symptoms. \u0000 \u0000 \u0000 \u0000Conclusions The fiber optic brush offers an exciting potential for treating scalp psoriasis.","PeriodicalId":20104,"journal":{"name":"Photodermatology, Photoimmunology and Photomedicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85945671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-04-01DOI: 10.1034/J.1600-0781.2002.180208_17.X
R. Sayre, J. Dowdy, J. Stanfield, J. Menter, K. Hatch
In the early 1990s NASA scientists developed a UV protective garment resembling a space suit for children afflicted with xeroderma pigmentosum. This garment together with gloves and face shield is able to protect the child allowing outdoor activities. We have examined all components of the garment within the framework of testing procedures developed for UV protective clothes and fabrics. The result is the garment developed more than 10 years ago meets today's standards for UV protective garments. Since photosensitive individuals, in general, may be affected by non-erythemogenic wavelengths, clothing for these patients require strategies not obvious for sunburn protection of normal individuals. These needs will be examined and recommendations made.
{"title":"017 Evaluation of the ‘NASA’ garment for children with xeroderma pigmentosum","authors":"R. Sayre, J. Dowdy, J. Stanfield, J. Menter, K. Hatch","doi":"10.1034/J.1600-0781.2002.180208_17.X","DOIUrl":"https://doi.org/10.1034/J.1600-0781.2002.180208_17.X","url":null,"abstract":"In the early 1990s NASA scientists developed a UV protective garment resembling a space suit for children afflicted with xeroderma pigmentosum. This garment together with gloves and face shield is able to protect the child allowing outdoor activities. \u0000 \u0000 \u0000 \u0000We have examined all components of the garment within the framework of testing procedures developed for UV protective clothes and fabrics. The result is the garment developed more than 10 years ago meets today's standards for UV protective garments. \u0000 \u0000 \u0000 \u0000Since photosensitive individuals, in general, may be affected by non-erythemogenic wavelengths, clothing for these patients require strategies not obvious for sunburn protection of normal individuals. These needs will be examined and recommendations made.","PeriodicalId":20104,"journal":{"name":"Photodermatology, Photoimmunology and Photomedicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91541482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-04-01DOI: 10.1034/J.1600-0781.2002.180208_1.X
B. Bergamo, C. Elmets
UVA-1 has distinct immunological effects which has allowed it to be useful for a number of cutaneous diseases that have been relatively resistant to other treatment modalities. These include urticaria pigmentosa, morphea/scleroderma and T-cell mediated diseases such as atopic dermatitis and cutaneous T-cell lymphoma. Since chronic hand dermatitis is also mediated by T-cells, we hypothesized that UVA- 1 would be an effective treatment for that disease as well. Five subjects with recalcitrant hand dermatitis caused by dyshidrosis and/or chronic irritancy were treated with a medium dose regimen of UVA- 1. This consisted of 15 treatments of 60 J/cm2 UVA 1 over 3 weeks. Subjects received a total of 900 J/cm2. A clinical scoring parameter, Dyshidrotic Area and Seventy Index Score (DASI), was administered to subjects prior to and following the UVA- 1 treatment course. Clinical photographs were also taken. All subjects showed improvement in hand dermatitis as demonstrated by clinical photographs and the DASI score (13 ± 5.35 before treatment; 6.3 ± 4.50 after treatment). UVA- 1 is an effective and rapid acting treatment for chronic hand dermatitis.
{"title":"001 UVA‐1 for the treatment of chronic hand dermatitis","authors":"B. Bergamo, C. Elmets","doi":"10.1034/J.1600-0781.2002.180208_1.X","DOIUrl":"https://doi.org/10.1034/J.1600-0781.2002.180208_1.X","url":null,"abstract":"UVA-1 has distinct immunological effects which has allowed it to be useful for a number of cutaneous diseases that have been relatively resistant to other treatment modalities. These include urticaria pigmentosa, morphea/scleroderma and T-cell mediated diseases such as atopic dermatitis and cutaneous T-cell lymphoma. Since chronic hand dermatitis is also mediated by T-cells, we hypothesized that UVA- 1 would be an effective treatment for that disease as well. Five subjects with recalcitrant hand dermatitis caused by dyshidrosis and/or chronic irritancy were treated with a medium dose regimen of UVA- 1. This consisted of 15 treatments of 60 J/cm2 UVA 1 over 3 weeks. Subjects received a total of 900 J/cm2. A clinical scoring parameter, Dyshidrotic Area and Seventy Index Score (DASI), was administered to subjects prior to and following the UVA- 1 treatment course. Clinical photographs were also taken. All subjects showed improvement in hand dermatitis as demonstrated by clinical photographs and the DASI score (13 ± 5.35 before treatment; 6.3 ± 4.50 after treatment). UVA- 1 is an effective and rapid acting treatment for chronic hand dermatitis.","PeriodicalId":20104,"journal":{"name":"Photodermatology, Photoimmunology and Photomedicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86174684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-04-01DOI: 10.1034/J.1600-0781.2002.180208_2.X
C. Maari, R. Bissonnette
Endogenous levels of protoporphyrin IX (PpIX) are known to be elevated in psoriatic plaques. Activation of PpIX by visible light after topical application of aminolevulinic acid has been shown to improve psoriasis. This study was designed to determine whether multiple exposures to blue light alone could improve psoriasis in patients exhibiting elevated endogenous PpIX levels. Patients and methods: Seventeen patients with at least two psoriatic plaques of 4 × 4 cm exhibiting elevated endogenous PpIX levels (as detected by in vivo fluorescence spectroscopy) were included in the study. Patients were required to discontinue all topical therapies for at least 2 weeks and systemic therapy for at least 8 weeks before treatment. One of the two plaques on each patient was exposed to 10 J/cm2 Of blue light from a fluorescence panel three times per week for 4 consecutive weeks. The other plaque was used as a non-exposed control. Blinded clinical evaluations were performed at baseline and every week during the 4-week treatment period as well as at 1 and 3 weeks after the last exposure. Psoriasis severity was assessed by evaluating on a scale of 0–4 the presence of erythema, induration, and desquamation. PpIX levels were measured before and after light exposure by in vivo fluorescence spectroscopy at week 1 and 4. Results: All patients completed the study without presenting treatment related side-effects. In vivo fluorescence spectroscopy demonstrated an almost complete photobleaching of PpIX in exposed plaques immediately after light exposure (P = 0.005). There was no significant difference between the mean psoriasis severity score of the exposed or control plaques before and after 12 exposures to blue light. Conclusion: Under the current conditions multiple exposures to blue light did not improve psoriasis.
{"title":"002 Multiple exposures to blue light does not improve psoriasis in patients with elevated endogenous levels of protoporphyrin IX","authors":"C. Maari, R. Bissonnette","doi":"10.1034/J.1600-0781.2002.180208_2.X","DOIUrl":"https://doi.org/10.1034/J.1600-0781.2002.180208_2.X","url":null,"abstract":"Endogenous levels of protoporphyrin IX (PpIX) are known to be elevated in psoriatic plaques. Activation of PpIX by visible light after topical application of aminolevulinic acid has been shown to improve psoriasis. This study was designed to determine whether multiple exposures to blue light alone could improve psoriasis in patients exhibiting elevated endogenous PpIX levels. \u0000 \u0000 \u0000 \u0000Patients and methods: Seventeen patients with at least two psoriatic plaques of 4 × 4 cm exhibiting elevated endogenous PpIX levels (as detected by in vivo fluorescence spectroscopy) were included in the study. Patients were required to discontinue all topical therapies for at least 2 weeks and systemic therapy for at least 8 weeks before treatment. One of the two plaques on each patient was exposed to 10 J/cm2 Of blue light from a fluorescence panel three times per week for 4 consecutive weeks. The other plaque was used as a non-exposed control. Blinded clinical evaluations were performed at baseline and every week during the 4-week treatment period as well as at 1 and 3 weeks after the last exposure. Psoriasis severity was assessed by evaluating on a scale of 0–4 the presence of erythema, induration, and desquamation. PpIX levels were measured before and after light exposure by in vivo fluorescence spectroscopy at week 1 and 4. \u0000 \u0000 \u0000 \u0000Results: All patients completed the study without presenting treatment related side-effects. In vivo fluorescence spectroscopy demonstrated an almost complete photobleaching of PpIX in exposed plaques immediately after light exposure (P = 0.005). There was no significant difference between the mean psoriasis severity score of the exposed or control plaques before and after 12 exposures to blue light. \u0000 \u0000 \u0000 \u0000Conclusion: Under the current conditions multiple exposures to blue light did not improve psoriasis.","PeriodicalId":20104,"journal":{"name":"Photodermatology, Photoimmunology and Photomedicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83938071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：